RSV Antibody Nirsevimab Lacks Second-Year Protection
Nirsevimab effectively reduced RSV-related hospitalizations in infants during their first year after administration, but the protection did not carry over to the second year. No benefit was seen for other hospitalizations beyond RSV.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Nirsevimab's RSV Protection Didn't Extend to Second Year.” Browse more stories.